Biliary tract cancer (BTC) is a form of gastrointestinal cancer that occurs in the bile duct, gallbladder, and ampulla of...
Home
The FDA approved the Investigational New Drug application for initiating a Phase 1/2 clinical study of YH001 in combination with...
The FDA has granted breakthrough therapy designation to the ROS1 inhibitor taletrectinib for the treatment of patients with advanced or...
The FDA has granted approval for pemigatinib (Pemazyre) to treat adult patients with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) and...
Pediatric patients aged 1 year and above with chronic graft-versus-host disease (cGVHD) can now benefit from ibrutinib following the FDA...
Novartis announced its intention to separate its generics and biosimilar division, Sandoz, into a new publicly traded standalone company through...
A new hope is looming for Myelofibrosis patients who experienced a suboptimal response to ruxolitinib and those who were JAK...
Tisagenlecleucel, sold under the brand name Kymriah was the first gene therapy approved by the FDA on 30 August 2017....
On August 11, 2022, the FDA gave the green light for accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) to treat adult...
On August 10, 2022, the Food and Drug Administration granted regular approval to capmatinib (Tabrecta) for adult patients with metastatic...
